Introducing Zembrin®

Zembrin® is the world’s leading researched and clinically studied extract of Sceletium tortuosum developed over more than a decade by an international team of scientists and physicians. With self-affirmed Generally Recognized As Safe (GRAS) status in USA, Zembrin® is an evidence-based botanical supplement that has been thoroughly studied for safety and efficacy in comprehensive preclinical as well as clinical studies.

Zembrin® is experiential – its effects can actually be experienced. It has mood-enhancing, anxiety-reducing and cognitive function enhancing activities, all of which can be of benefit to healthy people suffering from stress. The unique signature of Zembrin® is ‘alert serenity’.

The first standardized extract to have been made from Sceletium, Zembrin® is manufactured to the hightest international standarts at a certified EU-GMP manufacturer. It is produced from HG&H’s own elite naturally occurring chemotype of Sceletium – the first large-scale commercial cultivation of a Sceletium chemotype. The product has been patented, with granted patents and new patent applications and is the only Sceletium extract with published pharmacology. Note that all clinical and preclinical research on Zembrin® applies only to this proprietary standardized Sceletium extract, and not to other Sceletium-based products.

When HG&H set out to develop Zembrin® they were determined to formally acknowledge and reward the contribution of the San people who had originally discovered and used the South African plant Sceletium. This has been achieved through a formal benefit-sharing agreement with the South African San Council: Africa’s first prior-informed consent benefit-sharing agreement. As a result, Zembrin® is the only Sceletium product to carry the logo of its indigenous beneficiaries, the South African San Council.

Sceletium tortuosum is a protected species and wild-harvesting is not sustainable for commercial products. HG&H committed at the outset to only use cultivated plant material in the production of Zembrin® to avoid depleting threatened wild plant stocks, and to ensure consistent product quality. We have achieved this by investing in a highly successful new crop development programme, and cultivate our own selection of Sceletium on a large commercial scale.

These statements have not been evaluated by the Food and Drug Administration, or any other food and medicines regulatory authority. This product is not intended to prevent, treat, mitigate, or cure or diagnose any disease condition.